A pilot study to assess the acceptability and efficacy of acupuncture in alleviating vasomotor symptoms (hot flushes and night sweats) in Irish patients with prostate cancer receiving androgen deprivation therapy.

开始日期2024-08-30

申办/合作机构

University College Cork

[+1]

NCT06074237 / RecruitingN/AIIT

Improving Vaccine Counseling Skills Among Pediatric, Medicine/Pediatric and Family Medicine Residents Pilot Study: Evaluation, Education, and Promotion of Vaccine Confidence Using Educational Modules and Standardized Patient Encounters

Unfortunately, only 40% of US pediatric residency programs reported in a survey that vaccine safety and counseling training is provided to residents. The success of a residency curriculum focused on communication strategies with patients hesitant to receive the influenza vaccine has been demonstrated, finding a decreased rate of vaccination refusal in the post curricular period. In a recent 2020 study, it demonstrated the positive impact of an online vaccine curriculum on resident vaccine knowledge and self-reported confidence in counseling vaccine hesitant patients.
Providers have the potential to impact a substantial pediatric patient population. The outpatient clinics where the residents included in this study care for patients had 9942 pediatric visits in 2021. Each visit is an opportunity to talk with families about vaccines, address concerns and to administer vaccines when needed. The hypothesize is that interactive educational interventions using the online training modules combined with the standardized patient encounters will increase resident vaccine knowledge and confidence, and enhance communication and counseling skills, thereby improving vaccination rates of Human Papilloma Virus (HPV), Influenza, Measles/Mumps/Rubella (MMR) and Coronavirus (COVID-19) in the Beaumont residency clinics.

开始日期2024-04-25

申办/合作机构

William Beaumont Hospital Corp.

[+1]

NCT05507918 / WithdrawnN/AIIT

Effect of Pre-operative Oral Hydration on Post-operative Pain and Nausea in Adults Undergoing Tonsillectomy

Tonsillectomy is commonly described as one of the most painful procedures that an adult can undergo. This study's aim is to evaluate if pre-operative oral hydration has an impact in reducing post-operative pain, nausea and vomiting, and opioid medication use after adult tonsillectomies. Participants will be randomized to a low, medium and high fluid intake groups and will record fluid intake on the day before surgery. After surgery, participants will record their pain and nausea at timepoints up to 7 days post-operative. Medication use will be recorded up to the first post-operative follow-up visit with their physician.

开始日期2024-04-01

申办/合作机构

William Beaumont Hospital Corp.

100 项与 William Beaumont Hospital Corp. 相关的临床结果

登录后查看更多信息

0 项与 William Beaumont Hospital Corp. 相关的专利（医药）

登录后查看更多信息

2,307

项与 William Beaumont Hospital Corp. 相关的文献（医药）

2024-12-01·SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Assessing current handover practices in surgery: A survey of non-consultant hospital doctors in Ireland

Article

作者: Kavanagh, Dara O ; McNamara, Deborah A ; Toale, Conor ; Simiceva, Anastasija ; Ryan, Jessica M ; Eppich, Walter

BACKGROUND:

Handovers of care are potentially hazardous moments in the patient journey and can lead to harm if conducted poorly. Through a national survey of surgical doctors in Ireland, this paper assesses contemporary surgical handover practices and evaluates barriers and facilitators of effective handover.

METHODS:

After ethical approval and pre-testing with a representative sample, a cross-sectional, online survey was distributed to non-consultant hospital doctors (NCHDs) working in the Republic of Ireland. A mixed-methods approach was used, combining data using triangulation design.

MAIN FINDINGS:

A total of 201 responses were received (18.5%). Most participants were senior house officers or senior registrars (49.7% and 37.3%). Most people (85.1%) reported that information received during handover was missing or incorrect at least some of the time. One-third of respondents reported that a near-miss had occurred as a result of handover within the past three months, and handover-related errors resulted in minor (16.9%), moderate (4.9%), or major (1.5%) harm. Only 11.4% had received any formal training. Reported barriers to handover included negative attitudes, a lack of institutional support, and competing clinical activities. Facilitators included process standardisation, improved access to resources, and staff engagement.

CONCLUSIONS:

Surgical NCHDs working in Irish hospitals reported poor compliance with international best practice for handover and identified potential harms. Process standardisation, appropriate staff training, and the provision of necessary handover-related resources is required at a national level to address this significant patient safety concern.

2024-12-01·World Neurosurgery

Epidemiology of Spinal Cord Injury and Associated Mortality, Past and Present. Is There a Difference?

Article

作者: Vaccaro, Alexander R ; Gebeyehu, Teleale F ; Harrop, James ; Gebeyehu, Teleale F. ; Vaccaro, Alexander R. ; Thalheimer, Sara ; Mong, Eric R. ; Mong, Eric R

BACKGROUND:

The demographics of the population with spinal cord injury (SCI) have been dynamic over time, especially as a result of aging. This study investigated the patterns of SCI admissions by age in the United States over the past decade.

METHODS:

Data were evaluated (2010-2021), from the National Spinal Cord Injury Model Systems records. Patients were compared based on age (<70 and ≥70 years), analysis of mortality, neurologic level of injury, neurologic improvement, mortality by American Spinal Injury Association (ASIA) grade, and neurologic level of injury. Patients older than 70 years were defined as elderly.

RESULTS:

The mean age of the 8137 patients reviewed was 42.6 years (range, 15-88 years). The mean admission rate per year was 678 (range, 378-758). For the elderly versus the younger cohort, the incidence of falls decreased by 5% versus 3.3%, vehicle accidents increased by 3% versus 14%, high tetraplegia increased by 14.7% versus 22.5%, and low tetraplegia decreased by 12% versus 5.7%. In the elderly, ASIA grades A, B, and C decreased significantly, whereas ASIA grade D increased by 23.8%. In the younger cohort, ASIA grade A and B injuries decreased, whereas grades C and D increased, all <5%. Overall, 32.1% of those with ASIA grade A and 68% with ASIA grade B injuries improved within 1-2 years after injury. In-hospital and 1-year mortality decreased by 14.5% and 35.4%, respectively, in the elderly.

CONCLUSIONS:

The incidence of SCI increased. High cervical and incomplete injuries increased, whereas complete SCIs declined. In-hospital and 1-year mortality decreased. There was recovery in select cases of complete SCIs within 1 year.

2024-12-01·Minerva Gastroenterology

Helicobacter pylori infection does not influence the progression from gastroesophageal reflux disease to Barrett's esophagus to esophageal adenocarcinoma

Review

作者: Jaber, Fouad ; Edhi, Ahmed ; Khan, Zubair ; Inamdar, Sumant ; Thrift, Aaron P ; Aziz, Muhammad ; Desai, Tusar K ; Gangwani, Manesh K

INTRODUCTION:

We conducted a meta-analysis evaluating the overall risk of esophageal adenocarcinoma (EAC) in individuals with Helicobacter pylori infection, and a network meta-analysis to assess the role of H. pylori infection in the progression from Barrett's esophagus (BE) to EAC.

EVIDENCE ACQUISITION:

The MEDLINE, EMBASE and Cochrane databases were searched between 1988 and June 2023 for observational studies of H. pylori infection and the risk of EAC. Summary odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using the DerSimonian-Laird method. I² statistics were calculated to examine heterogeneity.

EVIDENCE SYNTHESIS:

Thirteen studies were included in the meta-analysis and 3 additional studies were included in the network meta-analysis. For comparisons with controls, individuals with H. pylori infection were 46% less likely to develop EAC than individuals without H. pylori infection (OR, 0.54; 95% CI: 0.46, 0.64), with low heterogeneity between studies (I²=4.4%). The magnitude of the inverse association was stronger in the two large cohort studies (OR=0.31) than in the 11 case-control studies (OR=0.55). When comparing to controls, the network meta-analysis of 6 studies showed that H. pylori infection was associated with a lower risk of GERD (OR=0.68) or BE (OR=0.59) or EAC (OR=0.54); however, H. pylori infection was not associated with risk of EAC in patients with BE (OR=0.91; 95% CI: 0.68, 1.21).

CONCLUSIONS:

This meta-analysis provides the strongest evidence yet that H. pylori infection is inversely associated with EAC. H. pylori does not appear to be associated with BE progression to EAC.

项与 William Beaumont Hospital Corp. 相关的新闻（医药）

2023-08-24

·PRNewswire

The Inner Circle Acknowledges, Elias Habib Kassab as a Top Pinnacle Healthcare Professional for his contributions to the field of Cardiology

DEARBORN, Mich., Aug. 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Elias Habib Kassab is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Cardiology. Continue Reading Elias Kassab Dr. Kassab pursued higher education at the American University in Beirut in Lebanon where he completed pre-medical coursework. He then earned a Doctor of Medicine degree from the Université Libre de Bruxelles in Brussels, Belgium; completed a residency and internship at Wayne State University; and a fellowship in cardiology with William Beaumont Hospital in Royal Oak, Michigan. Highly sought after for his leadership skills and expert knowledge of his vocation, Dr. Kassab is the founder, chief executive officer, and president of Dearborn Cardiology. He holds numerous roles in other facilities, including the chief executive and chief marketing officer of the Michigan Outpatient Vascular Institute since 2012 and chief executive officer of the Michigan Outpatient Vascular Institute's Ambulatory Surgery Center in 2023. Board-certified in cardiovascular disease through the American Board of Internal Medicine (ABIM), the doctor is considered an expert in interventional cardiology, and internal medicine. He is also board-certified in endovascular and vascular medicine by the American Board of Vascular Medicine and a registered physician in vascular interpretation. A testament to his vast knowledge, Dr. Kassab authored two chapters in Dr. Krishna Jain's book "Office-based Endovascular Centers" in 2019. Aside from his professional pursuits, the doctor enjoys art; wine; golf; exercise; cooking; traveling; and conducting research. In the coming years, he plans to continue building his brand and legacy by delivering the highest level of healthcare and wants to ensure that his facility leaves a mark as a leading, self-supervised cardiovascular outpatient center. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

AHA会议高管变更

2023-05-25

·BioSpace

Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the American Thoracic Society International Conference (ATS 2023) that was held in Washington DC between the 19th and 24th of May 2023. DR Girish Nair, MD - William Beaumont Hospital, Royal Oak, MI 48073, USAand principal investigator of the COVA study in the USA held an oral presentation of the results titled"COVA clinical study: Results from a double-blind, placebo-controlled phase 2-3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients." Biophytis also presented a poster that will be available on Biophytis' website . ATS 2023 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. The American Thoracic Society is at the forefront of basic and translational respiratory science and is an essential event for all respiratory researchers. It offers a unique opportunity to present the results in front of well-recognized peers from across the globe. Stanislas Veillet, CEO of Biophytis, said: " It was an honour to present these positive data to the scientific and medical community, showing a 44% reduction with Sarconeos (BIO101) vs placebo in the risk of respiratory failure or early death in hospitalized patients with severe COVID-19. This success is the result of the hard work of the clinical and medical teams involved in the COVA clinical study in France, Belgium, the USA and in Brazil. Sarconeos (BIO101) is the only innovative drug candidate in Europe or the United States targeting the Renin Angiotensin System (RAS) , impaired by SARS-CoV-2, that has demonstrated clinical efficacy in a Phase 2-3 study, as well as a very good safety profile. We are now moving forward with preparing regulatory filings to apply for conditional Marketing Authorization (cMA) in Europe and Emergency Use Authorization (EUA) in the USA" About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, planned to be developed as a treatment for sarcopenia in upcoming Phase 3 clinical trials in the United States, Brazil and Europe (SARA-31 and SARA-32). It has also been studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for thetreatment of Duchenne Muscular Dystrophy (DMD). The Company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information visit Disclaimer This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2022 Half Year Financial Report available on BIOPHYTIS website ( ) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Biophytis Contact for Investor Relations Nicolas Fellmann, CFO Investors@biophytis.com Media Contacts Antoine Denry: antoine.denry@taddeo.fr +33 6 18 07 83 27 Agathe Boggio: agathe.boggio@taddeo.fr +33 7 62 77 69 42 SOURCE: Biophytis View source version on accesswire.com:

临床结果临床3期临床2期

2023-05-03

·Business Wire

Nippon Life Selects H2O.ai to Transform Its Insurance Business With Machine Learning and Improve Customer Health

OSAKA, Japan & MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )-- H2O.ai , the AI Cloud leader, today announced a strategic partnership with Nippon Life Insurance Company, also known as Nissay in Japan. Specifically, the companies are announcing a partnership where Nippon Life Insurance Company will deploy H2O Driverless AI tools to better meet the needs of their policyholders, improve financial soundness of corporate health insurance unions and support health promotion and disease prevention. “AI is transforming the trillion dollar healthcare insurance industry, both the businesses themselves and the care they facilitate,” said Sri Ambati, CEO and founder of H2O.ai. “By helping Nippon Life advance their AI initiatives and create better customer experiences, the end result is literally, healthier people. And that’s what matters.” Machine learning is the foundational element of artificial intelligence and uses algorithms to detect and extract patterns in data to predict certain outcomes based on that analysis. H2O.ai systematically addresses multiple steps of the data science lifecycle with automation designed to reduce complexity across tasks and empower data scientists to implement AI projects with higher accuracy more efficiently. As the largest life insurance company in Japan, Nippon Life is in effect creating an entire in-house data science team by partnering with H2O.ai and making its technology pervasive throughout the organization. “H2O.ai will greatly contribute to the creation of advanced AI models that help us act as a socially responsible partner to our customers while also strengthening risk mitigation healthcare services in addition to risk preparedness insurance,” said Tetsuya Ueda, Executive Officer IT Planning Department at Nippon Life Insurance. The news follows on the heels of a notable year of customer partnerships for H2O.ai. AT&T recently launched an AI feature store powered by H2O.ai that lets anyone build forecasting and optimization tools for dynamic pricing, logistics and more. The Center for Digital Health Innovation at the University of California San Francisco used H2O.ai’s intelligent documentation product Document AI to automate the processing of 1.4 million faxed patient referrals and other documents that UCSF’s health system uses. About H2O.ai H2O is the leading open source machine learning platform on a mission to democratize AI. it distills the technical prowess of 30 Kaggle Masters into straightforward AI cloud products that solve powerful problems. Customers, community and partners are strategic investors in H2O.ai building a long term vision for using AI for Good. H2O.ai’s AI Engines of autoML Driverless AI, Hydrogen Torch and Document AI have transformed over 20,000 global organizations and over half of the Fortune 500 and household brands, including AT&T, Commonwealth Bank of Australia, Citi, Wells Fargo, PayPal, Chipotle, GlaxoSmithKline, Bon Secours Mercy Hospital, Kaiser Permanente, Procter & Gamble, PwC and Unilever. H2O.ai’s AI for Good program regularly supports nonprofit groups, foundations and communities in their efforts to advance education, healthcare, and environmental conservation, including identifying areas vulnerable to natural disasters and protecting endangered species. Join us on the movement at www.h2o.ai .

100 项与 William Beaumont Hospital Corp. 相关的药物交易

登录后查看更多信息

100 项与 William Beaumont Hospital Corp. 相关的转化医学

登录后查看更多信息